Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
16.723 / 17.032
#133777

Re: Farmas USA

Hilo muy interesante sobre el mercado en el 73-74. También le veo muchas similitudes. Seguro que las condiciones no son exactamente las mismas pero no me extrañaría algo similar, con un año complicado para el mercado. Ojalá no pase, pero por si acaso si el XBI rebota hasta esos $90 que puede apuntar y la situación es similar a la de ahora voy a soltar parte de la cartera de bios.

https://twitter.com/jsmian/status/1525481069633589249?s=20&t=TNSakiRExYr2cdN_c6W39A

I have found it useful to study the Nifty Fifty period and the 1973-1974 bear market, in particular, as it appears to have considerable overlap to the so-called FAANG stocks of today.

The Nifty Fifty were a group of premier growth stocks such as Xerox, IBM, Polaroid, McDonald’s, Disney, Pfizer, Merck, Procter & Gamble, Pepsi, and Coca-Cola that became institutional darlings in the early 1970s and sparked a radical shift away from value investing. At their peak in 1972, the Nifty Fifty traded at 42 times earnings, compared to S&P 500’s lofty average of 19.

They were considered “one-decision” stocks, to buy and hold for life, as quality franchises allowed them to earn high returns on capital well into the future. While this speculation has since proven to be correct (the average annual earnings growth was 11% through 1996), the delusion was that it didn’t matter what you paid for them.

A buy-and-hold investor who purchased a portfolio of Nifty Fifty stocks at the peak would still have matched the S&P 500 return over the next 25 years, 13% annually, but first they would have had to withstand a grueling decline.

The Dow had a good year in 1972, up 15%, but the advance was narrowing.
The Nifty Fifty stocks powered ahead while other smaller issues languished.

Fortune proclaimed, “The flush of robust prosperity is suffusing the economy.”

On January 11, 1973, the Dow rose to an all-time high of 1067. Barron’s article titled “Not a Bear Among Them” captured the sentiment.

L.O. Hooper of the brokerage W.E. Hutton & Co said, “The economy is becoming less and less vulnerable to big booms and big busts.”

The Dow’s initial move down from the January high was very sharp and within a month, it was off 100 points or almost 10%.

On January 23, President Nixon announced the end of the Vietnam war. The rise in inflation and interest rates started to hurt the economy and Nifty Fifty stocks. The Watergate scandal was also widening as top Nixon aides resigned at the end of April on charges of obstruction of justice. The Dow’s fall continued until late August into bear market territory when it finally bottomed at 857.

Over 300 public stock offerings were withdrawn as unsalable during this period.
“The stream of equity capital to US industry has run dry,” Business Week concluded.

From this point, the Dow surged 15% to 987 by the end of October, amid the Yom Kippur War and Vice President Spiro Agnew’s forced resignation.

Bulls were lulled into believing that a new leg up had begun.
“It’s time to turn bullish,” said Myron Simons of the brokerage Wooden & Co.

The two-month rally left the Dow just 6% shy of its record high in January. But the market internals were not confirming the advance. On October 19, Arab oil producing countries proclaimed an oil embargo to influence political events. Oil prices quadrupled over the next six months. Inflation was already spiraling out of control and the US economy entered a recession in November.

The Dow fell 20% in six weeks to 788 by December. For the full year, Treasury bills earned 8% compared to the Dow’s 15% loss. Valuations collapsed to a 20-year low.

The brokerage industry’s 1974 market outlook was filled with qualifications.
Barron’s columnist Alan Abelson wrote, “Never have so many said so much to such little purpose.” No one had any confidence in what the new year will bring.

After jumping back above 900 briefly in March, the Dow started to weaken again as impeachment hearings against Nixon began. Inflation and interest rates crept higher, while business profits buckled under the weight of a recession. In August, Nixon resigned. The Dow began another gut-wrenching decline.

“It was like a mudslide,” said Ralph Wanger of the Acorn Fund. “Every day you came in, watched the market go down another percent, and went home.”

The Dow dropped from 797 to 584 over the next two months, for a loss of 27%.

Investors finally capitulated in despair.
“There’s really no place to hide,” said Bill Grimsley of Investment Company of America.

Articles such as “Dow below 400?” from Forbes and “Is there no bottom?” from Newsweek were typical of the period.

Fortune ran a story titled “A Case for Gloom About Stocks,” which said the bear market might not yet be finished.

The Dow shot up 16% from the October low, but then retested it again in December to mark its final bottom.

The bear market of 1973-74 was over, 21 months after it began. 


The 45% decline was the worst ever since the Great Depression.

The Nifty Fifty were taken out and shot one by one” wrote a Forbes columnist.
From the highs, Coca-Cola fell 69%, Xerox 71%, McDonald’s 72%, Avon 86%, Disney 87% and Polaroid 91%.

The Dow’s January 1973 high would not be surpassed for another nine years.
#133778

Re: Farmas USA

NVAX

La semana pasada pasé a ver a la oncóloga y presione para que me pusieran la vacuna. Oficialmente hay un protocolo estatal que indica la vacuna de Novavax para inmunodeprimidos y demás (aunque creo que solo booster, no pauta completa; nadie sabe decirme) desde principios de marzo. 

Pues que no saben ni de qué les hablo y siguen pinchando Moderna. Nadie ha visto las dosis que tenían que llegar de esa vacuna.

Sigo en modo pupas. Subluxación del cartílago de la laringe ahora. Sin poder aleccionar corderos una temporada.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#133779

Re: Farmas USA

Mucho animo.

Lo que esta claro es que hay bloqueos por motivos X. Que motivos y quieb los desbloquea?esa es la cuestion.
Aqui de acuerdo con Pat, Nvax deberia ser muy pelma y repetitivo,hablar hablar y hablar para llegar a los fotos mediaticos. Sogue siebdo ub gran desconocido incluso para medicos que tiene tela...
#133780

Re: Farmas USA

Vaya racha llevas, animo querida, que no sea nada. 😘

Creo recordar que me pregunto Igonber despues del verano pasado que opinaba del tema NVAX. Y ya lo dije, que no sabia de que modo pero el mercado o las Big Pharmas no iban a permitir que un laboratorio de chichinabo se convirtiera en una de ellas. 

Deberia ser de manual leccion 1 para todo CEO. No vayas en solitario joder!


#133781

Re: Farmas USA

NVAX 
¡Mucho ánimo y que te recuperes pronto!

Yo llamé varias veces a mi centro de salud y conseguí que el médico me autorizara a ponerme el booster con NVAX. Anteriormente tuve que ponerme en contacto con la enfermera que llevaba el tema de vacunas y tampoco sabía nada, pero se informó y me dijo que iban a empezar a usarla y que tenía que pedirlo al médico (pero de esto hace casi 2 meses).

En teoría el uso tras problemas con mRNA está recogido como uno de los casos. Pero ni me han llamado ni tengo conocimiento de que se haya empezado a usar aquí en Aragón. No tengo prisa porque pillé Omicron, pero volveré a llamar a ver qué pasa porque sí que quiero vacunarme en 1 mes o así con la primera para antes del otoño ponerme la segunda de NVAX.

Tras mRNA parece que se necesitan 2 dosis de NVAX para que sea verdareramente efectiva. Era lo que apuntaban los pocos datoa que hay, y ahora de hecho así van a hacer el estudio de booster con la original y con la omicron que va a empezar este mes. 2 dosis de una u otra tras mRNA.
#133782

Re: Farmas USA

NVAX

Mucho ánimo, te deseo que te recuperes pronto.
#133783

Re: Farmas USA

Mucho ánimo
#133784

Re: Farmas USA

CMRX 
Otro desastre. Sale noticia acuerdo para vender los derechos de tembexa, sube hasta $5 (casi +20%). Me pienso venderlas porque me interesaba principalmente por esto y la pasta no es mucha. Pero no lo hago y anuncian después que paran un programa y que no van a tener AA para el programa más avanzado y que probablemente tendrán que hacer otro estudio. Había comprado unas pocas antes de ver las últimas noticias a $2.62 pero tras leer todo he vendido la mayoría a $2.72. Fuck! Así es complicado.

(Ya va por $2.2 y -50%).
Te puede interesar...
  1. Primeras dudas sobre la 'Trumponomics', ¿corrección o toma de beneficios?